Patents by Inventor Akinobu Maruyama

Akinobu Maruyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARYL OR HETEROARYL DERIVATIVE
    Publication number: 20230167073
    Abstract: A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar1, Ar2, X1-X3, R1, R3, R7, R8, L1, and L2 are as defined in the specifications.
    Type: Application
    Filed: April 15, 2021
    Publication date: June 1, 2023
    Applicant: Teijin Pharma Limited
    Inventors: Sakae SUGIYAMA, Takuya YOKOSAKA, Kunio MINAMIZONO, Asahi KAWANA, Toshiyuki KANEKO, Akinobu MARUYAMA, Kosuke SASAKI, Shinnosuke HOSODA, Masaki KOSHIMIZU, Susumu TAKEUCHI, Kenta KATO, Nagasree CHAKKA, Brett M. JOHNSON, Ryan D. WHITE, Wei ZHAO
  • Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
    Patent number: 11084814
    Abstract: The purpose of the present invention is to provide a compound that has excellent CDK4/6 inhibitory activity. The present invention is a compound represented by formula (I) or a pharmaceutically acceptable salt of the compound.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: August 10, 2021
    Assignee: Teijin Pharma Limited
    Inventors: Tsuyoshi Mizuno, Tomohiro Shimada, Gen Unoki, Akinobu Maruyama, Kosuke Sasaki, Takuya Yokosaka, Hiroshi Takahashi, Kyohei Horie, Yuri Sakai
  • PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20190367510
    Abstract: The purpose of the present invention is to provide a compound that has excellent CDK4/6 inhibitory activity. The present invention is a compound represented by formula (I) or a pharmaceutically acceptable salt of the compound.
    Type: Application
    Filed: November 27, 2017
    Publication date: December 5, 2019
    Applicant: Teijin Pharma Limited
    Inventors: Tsuyoshi MIZUNO, Tomohiro SHIMADA, Gen UNOKI, Akinobu MARUYAMA, Kosuke SASAKI, Takuya YOKOSAKA, Hiroshi TAKAHASHI, Kyohei HORIE, Yuri SAKAI
  • Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
    Patent number: 10124004
    Abstract: The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 13, 2018
    Assignee: Teijin Pharma Limited
    Inventors: Tsuyoshi Mizuno, Tomohiro Shimada, Gen Unoki, Masaru Ebisawa, Susumu Takeuchi, Kunio Minamizono, Kosuke Sasaki, Takuya Yokosaka, Junji Igarashi, Akinobu Maruyama, Hiroshi Takahashi, Kyohei Horie, Yuri Sakai
  • PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20180161329
    Abstract: The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 14, 2018
    Applicant: Teijin Pharma Limited
    Inventors: Tsuyoshi MIZUNO, Tomohiro SHIMADA, Gen UNOKI, Masaru EBISAWA, Susumu TAKEUCHI, Kunio MINAMIZONO, Kosuke SASAKI, Takuya YOKOSAKA, Junji IGARASHI, Akinobu MARUYAMA, Hiroshi TAKAHASHI, Kyohei HORIE, Yuri SAKAI
  • Pyrazine derivatives
    Patent number: 9856237
    Abstract: Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: January 2, 2018
    Assignee: Teijin Pharma Limited
    Inventors: Akinobu Maruyama, Susumu Takeuchi, Yoshimasa Takahashi
  • PYRIDINE DERIVATIVE
    Publication number: 20170190694
    Abstract: Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 6, 2017
    Applicant: Teijin Pharma Limited
    Inventors: Akinobu MARUYAMA, Hirofumi KAMADA, Mika FUJINUMA, Susumu TAKEUCHI, Hiroshi SAITOH, Yoshimasa TAKAHASHI
  • PYRAZINE DERIVATIVES
    Publication number: 20170152242
    Abstract: Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.
    Type: Application
    Filed: May 12, 2015
    Publication date: June 1, 2017
    Applicant: TEIJIN PHARMA LIMITED
    Inventors: Akinobu MARUYAMA, Susumu TAKEUCHI, Yoshimasa TAKAHASHI
  • NOVEL CRYSTALLINE POLYMORPHS OF PYRIDINE DERIVATIVE AND METHOD FOR PRODUCING THE SAME
    Publication number: 20170144987
    Abstract: Disclosed are crystals of 2-(5-chloropyridin-3-yl)-1-(2,5-dichlorobenzyl)-4-methyl-1H-imidazole-5-carboxylic acid useful as therapeutic or prophylactic agents for gout, hyperuricemia, and the like, and a method for producing the crystals.
    Type: Application
    Filed: May 12, 2015
    Publication date: May 25, 2017
    Applicant: TEIJIN PHARMA LIMITED
    Inventors: Hidetoshi MIYAMOTO, Hisae NOZATO, Akinobu MARUYAMA
  • Pyridine derivative
    Patent number: 9637469
    Abstract: Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: May 2, 2017
    Assignee: Teijin Pharma Limited
    Inventors: Akinobu Maruyama, Hirofumi Kamada, Mika Fujinuma, Susumu Takeuchi, Hiroshi Saitoh, Yoshimasa Takahashi
  • PYRIDINE DERIVATIVE
    Publication number: 20150284358
    Abstract: Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.
    Type: Application
    Filed: November 13, 2013
    Publication date: October 8, 2015
    Applicant: Teijin Pharma Limited
    Inventors: Akinobu Maruyama, Hirofumi Kamada, Mika Fujinuma, Susumu Takeuchi, Hiroshi Saitoh, Yoshimasa Takahashi